The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study




COVID-19; SARS-CoV-2; Hydroxychloroquine.


COVID-19 is an infectious disease caused by SARS-CoV-2, has a high transmission rate and has resulted in thousands of registered deaths worldwide. Currently, there are no clinical studies proving the effectiveness of specific drugs against SARS-Cov-2. However, previous experiences with similar viruses indicated potential effectiveness for certain drugs, including the use of Hydroxychloroquine (HCQ). At the beginning of the COVID-19 pandemic, the World Health Organization and the Ministry of Health of Brazil guided the use of HCQ as a therapeutic option. However, its role in viral infection by SARS-CoV-2, in addition to its real benefits in vivo, was unknown. Therefore, the aim of this study was to conduct a literature review on the use of HCQ in cases of COVID-19, and to discuss the results found in studies that performed in vitro and in vivo tests, in order to investigate its therapeutic efficacy. The review was carried out using descriptors in a computerized database. The antiviral efficacy of HCQ against SARS-CoV-2 in vitro has been described by several authors, inhibiting virus replication and mediating cytokine storm through its immunomodulatory effects. However, in vivo analyzes in complex organisms showed no effect on reducing viral load, as well as no clinical benefit to the patient. Thus, although preliminary in vitro results have shown to be positive and promising, evidence from randomized clinical trials indicated that HCQ did not cause the same effects in vivo against COVID-19.


Abella, B. S., Jolkovsky, E. L., Biney, B. T., Uspal, J. E., Hyman, M. C., Frank, I., Hensley, S. E., Gill, S., Vogl, D. T., Maillard, I., Babushok, D. V., Huang, A. C., Nasta, S. D., Walsh, J. C., Wiletyo, E. P., Gimotty, P. A., Milone, M. C., & Amaravadi, R. K. (2021). Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers. JAMA Internal Medicine, 181(2), 195.

Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., Ray, A. S., Cihlar, T., Siegel, D., Mackman, R. L., Clarke, M. O., Baric, R. S., & Denison, M. R. (2018). Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio, 9(2).

Andrade, K. R. C. de, Carvalho, V. K. da S., Farinasso, C. M., Lima, A. A. de, Silva, R. B., Wachira, V. K., Capucho, H. C., Souza, P. M. de, Vanni, T., Sachetti, C. G., & Rêgo, D. F. (2020). Terapia medicamentosa para infecções por coronavírus em humanos: revisão sistemática rápida. Ciência & Saúde Coletiva, 25(9), 3517–3554.

Ben-Zvi, I., Kivity, S., Langevitz, P., & Shoenfeld, Y. (2012). Hydroxychloroquine: From Malaria to Autoimmunity. Clinical Reviews in Allergy & Immunology, 42(2), 145–153.

Bortoli, R., & Santiago, M. (2007). Chloroquine ototoxicity. Clinical Rheumatology, 26(11), 1809–1810.

Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., Skipper, C. P., Nascene, A. A., Nicol, M. R., Abassi, M., Engen, N. W., Cheng, M. P., LaBar, D., Lother, S. A., MacKenzie, L. J., Drobot, G., Marten, N., Zarychanski, R., Kelly, L. E., … Hullsiek, K. H. (2020). A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. New England Journal of Medicine, 383(6), 517–525.

Brunton, L. L., Hidal-Dandan, R., & Knollmann, B. C. (2019). As bases farmacológicas da terapêutica de Goodman & Gilman. In Artmed (13a).

Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 178, 104787.

Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., Luo, Y., Ju, L., Zhang, J., & Wang, X. (2020). Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. MedRxiv, 2020.03.17.20037432.

Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020). A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care, 57, 279–283.

Estrela, C. (2018). Metodologia Científica: Ciência, Ensino, Pesquisa (Artes Médicas (Ed.); 3a.).

Fiocruz. (2021). Boletim observatório COVID-19 - Semanas epidemiológicas 10 e 11. Observatório Covid-19/Fiocruz, 7-20/3/21.

Furtado, R. H. M., Berwanger, O., Fonseca, H. A., Corrêa, T. D., Ferraz, L. R., Lapa, M. G., Zampieri, F. G., Veiga, V. C., Azevedo, L. C. P., Rosa, R. G., Lopes, R. D., Avezum, A., Manoel, A. L. O., Piza, F. M. T., Martins, P. A., Lisboa, T. C., Pereira, A. J., Olivato, G. B., Dantas, V. C. S., … Cavalcanti, A. B. (2020). Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. The Lancet, 396(10256), 959–967.

Furuta, Y., Komeno, T., & Nakamura, T. (2017). Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proceedings of the Japan Academy, Series B, 93(7), 449–463.

Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J.-M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 56(1), 105949.

Goldman, F. D., Gilman, A. L., Hollenback, C., Kato, R. M., Premack, B. A., & Rawlings, D. J. (2000). Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood, 95(11), 3460–3466.

Iser, B. P. M., Sliva, I., Raymundo, V. T., Poleto, M. B., Schuelter-Trevisol, F., & Bobinski, F. (2020). Suspected COVID-19 case definition: a narrative review of the most frequent signs and symptoms among confirmed cases. Epidemiologia e Serviços de Saúde, 29(3).

Jia, H. P., Look, D. C., Shi, L., Hickey, M., Pewe, L., Netland, J., Farzan, M., Wohlford-Lenane, C., Perlman, S., & McCray, P. B. (2005). ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia. Journal of Virology, 79(23), 14614–14621.

Jose, R. J., & Manuel, A. (2020). COVID-19 cytokine storm: the interplay between inflammation and coagulation. The Lancet Respiratory Medicine, 8(6), e46–e47.

Kawai, T., & Akira, S. (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature Immunology, 11(5), 373–384.

Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., & Ranst, M. Van. (2004). In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochemical and Biophysical Research Communications, 323(1), 264–268.

Ko, J. Y., Danielson, M. L., Town, M., Derado, G., Greenlund, K. J., Kirley, P. D., Alden, N. B., Yousey-Hindes, K., Anderson, E. J., Ryan, P. A., Kim, S., Lynfield, R., Torres, S. M., Barney, G. R., Bennett, N. M., Sutton, M., Talbot, H. K., Hill, M., Hall, A. J., … George, A. (2020). Risk Factors for Coronavirus Disease 2019 (COVID-19)–Associated Hospitalization: COVID-19–Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System. Clinical Infectious Diseases.

Kumar, M., Taki, K., Gahlot, R., Sharma, A., & Dhangar, K. (2020). A chronicle of SARS-CoV-2: Part-I - Epidemiology, diagnosis, prognosis, transmission and treatment. Science of The Total Environment, 734, 139278.

Lagneaux, L., Delforge, A., Carlier, S., Massy, M., Bernier, M., & Bron, D. (2001). Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors. British Journal of Haematology, 112(2), 344–352.

Lee, T. C., MacKenzie, L. J., McDonald, E. G., & Tong, S. Y. C. (2020). An observational cohort study of hydroxychloroquine and azithromycin for COVID-19: (Can’t Get No) Satisfaction. International Journal of Infectious Diseases, 98, 216–217.

Lima, C. M. A. de O. (2020). Information about the new coronavirus disease (COVID-19). Radiologia Brasileira, 53(2), V–VI.

Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., Li, Y., Hu, Z., Zhong, W., & Wang, M. (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery, 6(1), 6–9.

Maisonnasse, P., Guedj, J., Contreras, V., Behillil, S., Solas, C., Marlin, R., Naninck, T., Pizzorno, A., Lemaitre, J., Gonçalves, A., Kahlaoui, N., Terrier, O., Fang, R. H. T., Enouf, V., Dereuddre-Bosquet, N., Brisebarre, A., Touret, F., Chapon, C., Hoen, B., … Le Grand, R. (2020). Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature.

Manohar, S., Tripathi, M., & Rawat, D. (2014). 4-Aminoquinoline Based Molecular Hybrids as Antimalarials: An Overview. Current Topics in Medicinal Chemistry, 14(14), 1706–1733.

Mansilla, E., Marin, G. H., Nuñez, L., Drago, H., Sturla, F., Mertz, C., Rivera, L., Ichim, T., Riordan, N., & Raimondi, C. (2010). The Lysosomotropic Agent, Hydroxychloroquine, Delivered in a Biodegradable Nanoparticle System, Overcomes Drug Resistance of B-Chronic Lymphocytic Leukemia Cells In Vitro. Cancer Biotherapy and Radiopharmaceuticals, 25(1), 97–103.

Martinez, M. A. (2020). Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. Antimicrobial Agents and Chemotherapy, 64(5).

Mates, M., Nesher, G., & Zevin, S. (2007). Quinines--past and present. Harefuah, 146(7), 560–562, 572.

Mauthe, M., Orhon, I., Rocchi, C., Zhou, X., Luhr, M., Hijlkema, K.-J., Coppes, R. P., Engedal, N., Mari, M., & Reggiori, F. (2018). Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy, 14(8), 1435–1455.

Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet, 395(10229), 1033–1034.

Ministerio da Saúde. (2021). Painel Coronavirus.

Ministério da Saúde. (2020). Ministério da Saúde amplia orientações para uso de Cloroquina.

Mitjà, O., & Clotet, B. (2020). Use of antiviral drugs to reduce COVID-19 transmission. The Lancet Global Health, 8(5), e639–e640.

Nosál, R., Jančinová, V., & Petríková, M. (1995). Chloroquine inhibits stimulated platelets at the arachidonic acid pathway. Thrombosis Research, 77(6), 531–542.

Oliveira, W. K. de, Duarte, E., França, G. V. A. de, & Garcia, L. P. (2020). Como o Brasil pode deter a COVID-19. Epidemiologia e Serviços de Saúde, 29.

Organização Pan-Americana da Saúde. (2020). FOLHA INFORMATIVA COVID-19 - ESCRITÓRIO DA OPAS E DA OMS NO BRASIL.

Page, F. (1951). TREATMENT OF LUPUS ERYTHEMATOSUS WITH MEPACRINE. The Lancet, 258(6687), 755–758.

Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica (N. UFSM (Ed.); 1a).

Rainsford, K. D., Parke, A. L., Clifford-Rashotte, M., & Kean, W. F. (2015). Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology, 23(5), 231–269.

Rempenault, C., Combe, B., Barnetche, T., Gaujoux-Viala, C., Lukas, C., Morel, J., & Hua, C. (2018). Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Annals of the Rheumatic Diseases, 77(1), 98–103.

Retallack, H., Di Lullo, E., Arias, C., Knopp, K. A., Laurie, M. T., Sandoval-Espinosa, C., Mancia Leon, W. R., Krencik, R., Ullian, E. M., Spatazza, J., Pollen, A. A., Mandel-Brehm, C., Nowakowski, T. J., Kriegstein, A. R., & DeRisi, J. L. (2016). Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proceedings of the National Academy of Sciences, 113(50), 14408–14413.

Rolain, J.-M., Colson, P., & Raoult, D. (2007). Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. International Journal of Antimicrobial Agents, 30(4), 297–308.

Rynes, R. I., & Bernstein, H. N. (1993). Ophthalmologic safety profile of antimalarial drugs. Lupus, 2 Suppl 1, S17-9.

Schrezenmeier, E., & Dörner, T. (2020). Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nature Reviews Rheumatology, 16(3), 155–166.

Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., Spahn, J. E., Bauer, L., Sellers, S., Porter, D., Feng, J. Y., Cihlar, T., Jordan, R., Denison, M. R., & Baric, R. S. (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications, 11(1), 222.

Skipper, C. P., Pastick, K. A., Engen, N. W., Bangdiwala, A. S., Abassi, M., Lofgren, S. M., Williams, D. A., Okafor, E. C., Pullen, M. F., Nicol, M. R., Nascene, A. A., Hullsiek, K. H., Cheng, M. P., Luke, D., Lother, S. A., MacKenzie, L. J., Drobot, G., Kelly, L. E., Schwartz, I. S., … Boulware, D. R. (2020).

Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. Annals of Internal Medicine, 173(8), 623–631.

Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., Wu, Y., Xiao, W., Liu, S., Chen, E., Chen, W., Wang, X., Yang, J., Lin, J., Zhao, Q., Yan, Y., Xie, Z., Li, D., Yang, Y., … Xie, Q. (2020).

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ, m1849.

Tett, S., Cutler, D., Day, R., & Brown, K. (1989). Bioavailability of hydroxychloroquine tablets in healthy volunteers. British Journal of Clinical Pharmacology, 27(6), 771–779.

The RECOVERY Collaborative Group. (2020). Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine, 383(21), 2030–2040.

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30(3), 269–271.

WHO Solidarity trial consortium. (2021). Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. New England Journal of Medicine, 384(6), 497–511.

Winkler, E. S., Bailey, A. L., Kafai, N. M., Nair, S., McCune, B. T., Yu, J., Fox, J. M., Chen, R. E., Earnest, J. T., Keeler, S. P., Ritter, J. H., Kang, L.-I., Dort, S., Robichaud, A., Head, R., Holtzman, M. J., & Diamond, M. S. (2020). SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nature Immunology, 21(11), 1327–1335.

Wolfe, F., & Marmor, M. F. (2010). Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care & Research, 62(6), 775–784.

World Health Organization. (2021). WHO CORONAVIRUS DISEASE (COVID-19) DASHBOARD.

Xavier, A. R., Silva, J. S., Almeida, J. P. C. L., Conceição, J. F. F., Lacerda, G. S., & Kanaan, S. (2020). COVID-19: clinical and laboratory manifestations in novel coronavirus infection. Jornal Brasileiro de Patologia e Medicina Laboratorial, 56.

Xia, S., Zhu, Y., Liu, M., Lan, Q., Xu, W., Wu, Y., Ying, T., Liu, S., Shi, Z., Jiang, S., & Lu, L. (2020). Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cellular & Molecular Immunology, 17(7), 765–767.

Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., Zhan, S., Lu, R., Li, H., Tan, W., & Liu, D. (2020). In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases, 71(15), 732–739.

Zhang, X., Wu, J., Du, F., Xu, H., Sun, L., Chen, Z., Brautigam, C. A., Zhang, X., & Chen, Z. J. (2014). The Cytosolic DNA Sensor cGAS Forms an Oligomeric Complex with DNA and Undergoes Switch-like Conformational Changes in the Activation Loop. Cell Reports, 6(3), 421–430.

Zhou, Q., McCracken, M. A., & Strobl, J. S. (2002). Control of Mammary Tumor Cell Growth in Vitro by Novel Cell Differentiation and Apoptosis Agents. Breast Cancer Research and Treatment, 75(2), 107–117.

Zimmermann, P., Ziesenitz, V. C., Curtis, N., & Ritz, N. (2018). The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying Mechanisms. Frontiers in Immunology, 9.



How to Cite

SILVA, A. B.; GALBRAITH, B. B. de S. .; BORGES, C. L. R. .; COSTA, D. P. de R. S. .; BINES, D.; LOPES, G. C. K.; BEKIERMAN, H. B. V. .; PORTO, H. F. B. .; SEABRA, J. M. de A. .; SANTOS, J. V. .; CABRAL , M. V. de S. .; SAUGO, P. H.; ANDRADE , V. G. de .; AZEVEDO, P. L. The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study. Research, Society and Development, [S. l.], v. 10, n. 10, p. e444101019118, 2021. DOI: 10.33448/rsd-v10i10.19118. Disponível em: Acesso em: 23 feb. 2024.



Health Sciences